FOLD
Income statement / Annual
Last year (2025), Amicus Therapeutics Inc's total revenue was $634.21 M,
an increase of 20.05% from the previous year.
In 2025, Amicus Therapeutics Inc's net income was -$27.11 M.
See Amicus Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$634.21 M |
$528.30 M |
$399.36 M |
$329.23 M |
$305.51 M |
$260.89 M |
$182.24 M |
$91.25 M |
$36.93 M |
$4.96 M |
| Cost of Revenue |
$80.39 M
|
$52.94 M
|
$37.33 M
|
$38.60 M
|
$34.47 M
|
$31.04 M
|
$21.96 M
|
$14.40 M
|
$6.24 M
|
$833.00 K
|
| Gross Profit |
$553.82 M
|
$475.35 M
|
$362.03 M
|
$290.63 M
|
$271.05 M
|
$229.84 M
|
$160.27 M
|
$76.84 M
|
$30.69 M
|
$4.13 M
|
| Gross Profit Ratio |
0.87
|
0.9
|
0.91
|
0.88
|
0.89
|
0.88
|
0.88
|
0.84
|
0.83
|
0.83
|
| Research and Development Expenses |
$135.84 M
|
$109.36 M
|
$152.38 M
|
$276.68 M
|
$272.05 M
|
$308.44 M
|
$286.38 M
|
$270.90 M
|
$149.31 M
|
$104.79 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$127.20 M
|
$0.00
|
$71.15 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$383.49 M
|
$323.38 M
|
$275.27 M
|
$213.04 M
|
$192.71 M
|
$156.41 M
|
$169.86 M
|
$127.20 M
|
$88.67 M
|
$71.15 M
|
| Other Expenses |
$0.00
|
$17.74 M
|
$11.59 M
|
$13.04 M
|
$12.72 M
|
$11.99 M
|
$8.07 M
|
-$5.63 M
|
$6.01 M
|
-$4.79 M
|
| Operating Expenses |
$519.33 M
|
$450.48 M
|
$439.24 M
|
$502.75 M
|
$477.48 M
|
$476.84 M
|
$464.31 M
|
$402.32 M
|
$241.57 M
|
$179.19 M
|
| Cost And Expenses |
$599.72 M
|
$503.42 M
|
$476.57 M
|
$541.35 M
|
$511.95 M
|
$507.88 M
|
$486.27 M
|
$416.72 M
|
$247.81 M
|
$180.02 M
|
| Interest Income |
$3.32 M
|
$5.41 M
|
$7.08 M
|
$3.02 M
|
$509.00 K
|
$3.23 M
|
$10.25 M
|
$10.46 M
|
$4.10 M
|
$1.60 M
|
| Interest Expense |
$46.16 M
|
$49.60 M
|
$50.15 M
|
$37.12 M
|
$32.47 M
|
$22.43 M
|
$18.87 M
|
$22.40 M
|
$17.24 M
|
$5.40 M
|
| Depreciation & Amortization |
$7.46 M
|
$8.55 M
|
$7.87 M
|
$5.34 M
|
$6.21 M
|
$8.85 M
|
$4.78 M
|
$4.22 M
|
$3.59 M
|
$3.24 M
|
| EBITDA |
$53.81 M |
$29.39 M |
-$92.08 M |
-$199.58 M |
-$202.87 M |
-$242.98 M |
-$332.26 M |
-$322.47 M |
-$428.29 M |
-$195.14 M |
| EBITDA Ratio |
0.08
|
0.06
|
-0.23
|
-0.61
|
-0.66
|
-0.93
|
-1.82
|
-3.53
|
-11.6
|
-39.36
|
| Operating Income Ratio |
0.05
|
0.05
|
-0.19
|
-0.64
|
-0.68
|
-0.95
|
-1.67
|
-3.6
|
-11.97
|
-36.69
|
| Total Other Income/Expenses Net |
-$34.30 M
|
-$53.63 M
|
-$72.89 M
|
-$29.92 M
|
-$35.12 M
|
-$27.26 M
|
-$51.87 M
|
-$23.61 M
|
-$7.14 M
|
-$21.89 M
|
| Income Before Tax |
$191.00 K
|
-$28.76 M
|
-$150.10 M
|
-$242.04 M
|
-$241.55 M
|
-$274.25 M
|
-$355.91 M
|
-$349.09 M
|
-$449.12 M
|
-$203.78 M
|
| Income Before Tax Ratio |
0
|
-0.05
|
-0.38
|
-0.74
|
-0.79
|
-1.05
|
-1.95
|
-3.83
|
-12.16
|
-41.1
|
| Income Tax Expense |
$27.30 M
|
$27.35 M
|
$1.48 M
|
-$5.47 M
|
$8.91 M
|
$2.60 M
|
$478.00 K
|
-$94.00 K
|
-$165.12 M
|
-$3.74 M
|
| Net Income |
-$27.11 M
|
-$56.11 M
|
-$151.58 M
|
-$236.57 M
|
-$250.46 M
|
-$276.85 M
|
-$356.39 M
|
-$349.00 M
|
-$284.00 M
|
-$200.04 M
|
| Net Income Ratio |
-0.04
|
-0.11
|
-0.38
|
-0.72
|
-0.82
|
-1.06
|
-1.96
|
-3.82
|
-7.69
|
-40.35
|
| EPS |
-0.0879 |
-0.18 |
-0.51 |
-0.82 |
-0.92 |
-1.07 |
-1.48 |
-1.88 |
-1.85 |
-1.49 |
| EPS Diluted |
-0.0879 |
-0.18 |
-0.51 |
-0.82 |
-0.92 |
-1.07 |
-1.48 |
-1.88 |
-1.85 |
-1.49 |
| Weighted Average Shares Out |
$308.36 M
|
$304.38 M
|
$295.16 M
|
$289.06 M
|
$271.42 M
|
$258.87 M
|
$240.42 M
|
$185.79 M
|
$153.36 M
|
$134.40 M
|
| Weighted Average Shares Out Diluted |
$308.36 M
|
$304.38 M
|
$295.16 M
|
$289.06 M
|
$271.42 M
|
$258.87 M
|
$240.42 M
|
$185.79 M
|
$153.36 M
|
$134.40 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
